View More Recent Stories

Jan 11, 2021 07:00AM Sosei Heptares to present at 39th Annual J.P. Morgan Healthcare Conference
Jan 5, 2021 02:00AM Sosei Heptares to Regain Worldwide Rights to Muscarinic Agonist Programs
Dec 22, 2020 03:00AM Sosei Heptares and Captor Therapeutics Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design
Dec 20, 2020 07:01PM Sosei Heptares and GSK Enter Global Collaboration and License Agreement Targeting Immune Disorders of the Digestive System
Dec 1, 2020 03:05AM Sosei Heptares and Biohaven Enter Global Collaboration and License Agreement to Advance Novel Small-Molecule CGRP Antagonist Portfolio
Nov 20, 2020 04:05AM Sosei Heptares' COVID-19 Program Identifies Potent Broad Spectrum Anti-Viral Small Molecules for Further Development
Nov 11, 2020 02:55AM Sosei Heptares Operational Highlights and Consolidated Results for the Nine Months ended 30 September 2020
Nov 2, 2020 07:46AM Sosei Heptares and Aditum Bio create new company - Tempero Bio - to advance the clinical development of mGlu5 NAM program in neurological diseases
Sep 3, 2020 04:57AM Sosei Heptares Appoints Top-Ranked Investment Analyst Hironoshin Nomura as Senior Vice President, Investor Relations and Corporate Strategy
Jul 16, 2020 02:47AM Sosei Heptares Successfully Raises US$200 million in International Offering of New Shares and Convertible Bonds
View More Recent Stories